Therefore, to evaluate mtDNA damage for use as a pharmacodynamic biomarker of LRRK2 kinase inhibitors in clinical trials and compare it to other candidate target engagement biomarkers, we examined healthy control and PD LRRK2 G2019S patient-derived Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL); detailed demographic information can be found in Supplemental Table S1. The gene discussed is LRRK2; the disease is Parkinson disease.